First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients.

Purpose:124I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducted a first-in-human study of microdose 124I-PU-H71 for positron emission tomography (PET) to study in vivo biodistribution, pharmacokinetics, metabolism, and safety; and the feasibility of epichaperome-targeted tumor imaging. Experimental Design: Adult patients with cancer (n=30) received 124I-PU-H71 tracer (201±12 MBq,